Home » Newsletters » BioWorld Science

BioWorld Science

March 19, 2020

View Archived Issues

NEFAs nefarious role in pancreatitis

Enrollment begins in phase I study of AmnioBoost for treatment of COVID-19

Opioid analgesic CYX-6 displays antinociception without constipation, respiratory depression

Cellenkos seeks to advance CK-0802 for CoV-ARDS

CanSino receives clearance in China for phase I trials with Ad5-nCoV candidate vaccine for COVID-19

SELLAS presents positive data from phase II VADIS study of nelipepimut-S

Mateon to develop OT-101 against COVID-19

Positive final data from phase Ib study of Allocetra-OTS in severe sepsis

Pneumagen announces new program to target COVID-19 infections

Armata awarded up to USD 5 million from CFF for the development AP-PA02

The University of Washington discloses new ERN1/ERN2 inhibitors

Clinical data published on vincristine and irinotecan in children with Wilms tumor

IDO-1 inhibitors discovered at Bristol-Myers Squibb

Testing, testing: first repurposing trial for COVID-19 falls flat

Phase II data reported for preoperative letrozole in DCIS

Zolgensma approved in Japan for SMA

Global phase III trial to evaluate Actemra for severe COVID-19 pneumonia

Researchers identify novel biomarkers in Crohn's disease

Pfizer reports phase III data on 20-valent pneumococcal conjugate vaccine in vaccine-naive adults

Cellphire cleared to begin phase II study of Thrombosomes in bleeding patients with thrombocytopenia

Northwestern University synthesizes new glucosylceramidase modulators

Xenon Pharmaceuticals patents Nav1.6 channel blockers

New antitubercular compounds identified at Monash University

Identification and optimization of isoxazole amides as potent and selective SMYD3 inhibitors

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...